

## Invitation to presentation of Q-linea's Year-end report Q4-2024 on February 28, 2025

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), published the company's Year-end report for the period January – December 2024 on Friday 28 February 2025, at 07:30 a.m. (CEST).

Q-linea invites investors, analysts and the media to an audiocast and teleconference (in English) today, 28 February 2025, at 1:00 to 2:00 p.m. (CEST). CEO Stuart Gander and CFO Christer Samuelsson will present Q-linea, comment on the year-end report for 2024 financial year and respond to questions.

To participate via webcast, please visit the following link: <https://q-linea.events.inderes.com/q4-report-2024>

There will be an opportunity to ask questions in writing at the webcast.

If you would like to ask questions verbally via conference call, please register at the following link: <https://events.inderes.com/q-linea/q4-report-2024/dial-in>

You will receive a telephone number and a meeting ID to log into the conference call after registering. There will be an opportunity to ask questions verbally during the conference call.

### For more information, please contact:

Stuart Gander, President & CEO, Q-linea  
[Stuart.Gander@qlinea.com](mailto:Stuart.Gander@qlinea.com)  
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB  
[Christer.Samuelsson@qlinea.com](mailto:Christer.Samuelsson@qlinea.com)  
+46 (0) 70-600 15 20

### About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit [www.qlinea.com](http://www.qlinea.com)

**Attachments**

Invitation to presentation of Q-linea's Year-end report Q4-2024 on February 28, 2025